Planned adaptive design phase II trial of interleukin 24 gene therapy in patients with recurrent head and neck cancer.

Trial Profile

Planned adaptive design phase II trial of interleukin 24 gene therapy in patients with recurrent head and neck cancer.

Planning
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2014

At a glance

  • Drugs Interleukin 24 gene therapy-MultiVir (Primary) ; Antineoplastics
  • Indications Head and neck cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors MultiVir
  • Most Recent Events

    • 03 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top